

USHP Annual Meeting
Saturday, September 14, 2013
University of Utah Health Sciences Education Building
(East of College of Pharmacy)
26 South 2000 East
Salt Lake City, Utah 84112

2013 Registration

Option 1 – Fill out this form and mail with check to:
USHP, PO Box 58356, Salt Lake City, Utah 84158
Registration must be postmarked by September 1, 2013

Option 2 – Register online and pay via credit card or paypal at www.ushp.org

Space is Limited – Register Early!

Name:

Mailing Address:

City, State, Zip:

Preferred Phone:

Dietary Needs?:

Email Address:

CPE Monitor ID# (required)

Birth Month/Day (required)

/

Note: CPE Monitor ID, Birth Month/Day required for ACPE credit

After September 1st, add \$40 to the below published price. An e-mail confirmation will be sent to the above indicated address.

Pricing Schedule

	Member	Non-Member
Pharmacists	___ \$100	___ \$175
Technician	___ \$60	___ \$100
Student	___ \$40	

Meeting Agenda

USHP Annual Meeting
September 14, 2013
University of Utah Health Sciences Building
26 South 2000 East
Salt Lake City, Utah 84112

7:00 AM – 7:30 AM	Registration, Check-In & Breakfast	
7:30 AM – 8:00 AM	Welcome/ Business Meeting (Awards, Install Officers)	
8:00 AM – 9:00 AM	Keynote Presentation: Trials and Tribulations of Lipid Management in 2013 (P/T) Stuart Haines, PharmD, BCPS, BCACP, BC-ADM	
9:00 AM – 10:00 AM	Compounding Paradigm Shift: Public Policies and Change in Regulatory Landscape (Part 1) (P/T) Jim Ruble, PharmD, JD	
10:00 AM – 10:15 AM	Break/Snacks/Exhibitors	
10:15 AM – 11:15 PM	Compounding Paradigm Shift: Public Policies and Change in Regulatory Landscape (Part 2) (P/T) Trip Hoffman, PharmD	
11:15 AM – 12:45 PM	Lunch/Exhibitors/Poster Session HSEB 2110 and 2120 Poster Session starts at 1200	
12:50 PM – 1:50 PM	Chemotherapy Cliff Notes: A General Review of Chemotherapy Associated Toxicities (P/T) Makala Pace, PharmD, BCOP	The Ever Changing Pharmacokinetics of the Pediatric Patient(P/T) Emily Benefield, PharmD, BCPS
1:55 PM – 2:55 PM	Hepatitis C Virus: A Treatment Revolution (P) Alissa Raines, PharmD, BCPS Travis Dick, PharmD, MBA, BCPS	Medication Assistance Programs and Resources (P/T) Jan Bird, CPhT Brooke Booth, CPhT
3:00 PM – 4:00 PM	Acute Brain Dysfunction (Delirium) and Post-ICU Syndrome (P) Ann Marie Prazak, MS, PharmD, BCPS Tyler Sledge, PharmD	Medical Marijuana: Blowing Away the Smoke (P/T) Chris Stock, PharmD, BCPP
4:00 – 5:00 PM	Pharmacy Advocacy: Physician Dispensing Laws in Utah (P/T) Missy Duke, PharmD, MS, BCPS	
3:00 PM – 4:30 PM	Student Programming Residency “speed dating”	

P = Accredited for Pharmacists

T= Accredited for Technicians

The target audience is Pharmacists and Pharmacy Technicians.

All educational activities are knowledge-based activities

Educational Objectives

8:00 AM

Trials and Tribulations of Lipid Management in 2013

Stuart Haines, PharmD, BCPS, BCACP, BC-ADM

Professor and Vice Chair for Clinical Services Department of Pharmacy Practice and Science Faculty Fellow , University of Maryland

#0167-0000-13-032-L01-P/T

Objectives (pharmacists)

1. Examine the utility of traditional and emerging approaches to cardiovascular risk assessment.
2. Evaluate the clinical trials that employed drug therapies for dyslipidemia published since January 2010.
3. Given a patient case, recommend a risk assessment and lipid management strategy that is consistent with the available evidence.

Objectives (technicians)

1. Identify at least 3 CVD risk assessment calculators.
 2. State which drug therapy combinations for dyslipidemia have been studied in clinical trials.
 3. State the most common side effects associated with statin plus niacin combination therapy.
-

9:00 AM

Compounding Paradigm Shift: Public Policies and Change in Regulatory Landscape (Part 1)

Jim Ruble, PharmD, JD

Pharmacotherapy Assistant Professor (Clinical), University of Utah College of Pharmacy

#0167-0000-13-029-L03-P/T

Objectives (pharmacists)

1. Explain the historical development of the compounding “safe harbor” exemption in the Federal Food Drug and Cosmetic Act.
2. List three (3) key stakeholders in the compounding safety dialogue
3. Discuss two (2) regulatory enforcement tools that Federal Agencies can use in their oversight of compounding activities.
4. Describe federal initiatives to increase surveillance and oversight of compounding.
5. Identify three (3) trends in public policy that may impact the delivery of compounded products to patients.

Objectives (technicians)

1. Identify a key stakeholder in the compounding safety dialogue.
 2. Discuss FDA regulation to determine compounding v manufacturing.
 3. Explain one (1) possible change in the oversight of compounding by federal authorities.
-

10:15 AM

Compounding Paradigm Shift: Public Policies and Change in Regulatory Landscape (Part 2)

Trip Hoffman, PharmD

Clinical Pharmacist, University Pharmacy

Utah Board of Pharmacy Member, Compounding Task Force Advisory Board (Chair)

#0167-0000-13-031-L03-P/T

Objectives (pharmacist)

1. Describe one (1) change to Utah state law regarding compounding and how this impacts your compounding pharmacy.
2. Distinguish the two (2) governing jurisdictions with oversight on the compounding industry
3. List three (3) broad areas of focus to achieve and meet the objectives of USP 797
4. Identify three (3) steps to becoming USP compliant and updating your Standard Operating Procedures.
5. Describe two (2) essential tools that aid in improving compliance and patient safety.

Objectives (technicians)

1. Identify the Utah state law regarding compounding.
 2. List one (1) governing jurisdictions with oversight on compounding activities.
 3. Describe one (1) essential tool that aids in improving compliance and improving patient safety.
-

12:50 PM

Chemotherapy Cliff Notes: A General Review of Chemotherapy and its Associated Toxicities

Makala Pace, PharmD, BCOP

Hematology & Oncology Clinical Pharmacist, Huntsman Cancer Hospital

0167-0000-13-023-L01-P/T

Objectives (pharmacists)

1. Analyze the rationale for using systemic chemotherapy to treat cancer.
2. Compare & contrast the common toxicities of systemic chemotherapy.
3. Devise a management strategy for common chemotherapy toxicities.

Objectives (technicians)

1. Explain one reason for using systemic chemotherapy to treat cancer.
 2. List two classes of chemotherapy medications.
 3. Identify two common chemotherapy toxicities.
-

12:50 PM

The Ever Changing Pharmacokinetics of the Pediatric Patient

Emily Benefield, PharmD, BCPS

Clinical Pharmacist, Pediatric Intensive Care, Primary Children's Medical Center

0167-0000-13-030-L01-P/T

Objectives (pharmacists)

1. Compare the volume of distribution for gentamicin in neonates & adults.
2. List the metabolic pathway functioning at full capacity at birth.
3. Evaluate the need for renal dose adjustment of medications using the bedside Schwartz equation.
4. Identify the recommended max weight used for weight-based dosing of medications.

Objectives (technicians)

1. Define the terms premature neonate, neonate, child, & adolescent.
 2. Describe the benefits of using standard concentrations in pediatric medication preparation.
 3. List two high-risk medications with multiple available concentrations that are commonly used for pediatric patients.
-

1:55 PM

Hepatitis C Virus: A Treatment Revolution

Alissa Raines, PharmD, BCPS

Solid Organ Transplant Clinical Pharmacy Specialist, Intermountain Medical Center

Travis Dick, PharmD, MBA, BCPS

Solid Organ Transplant Clinical Pharmacy Specialist, Intermountain Medical Center

0167-0000-13-027-L01-P

Objectives (pharmacists)

1. Outline the epidemiology and pathophysiology of hepatitis c virus (HCV).
 2. Describe direct acting antiviral agents for the treatment of HCV.
 3. Forecast agents in the pipeline for the management of HCV.
-

1:55 PM

Medication Assistance Programs and Resources

Jan Bird, CPhT

Pharmacy Charity Eligibility Coordinator & Pharmacy Technician, Intermountain Medical Center

Utah Board of Pharmacy Member

Brooke Booth, CPhT

Pharmacy Charity Eligibility Counselor & Pharmacy Technician, Intermountain Medical Center

0167-0000-13-028-L04-P/T

Objectives (pharmacists and technicians)

1. Identify unique pharmacy technician positions as they apply to patient assistance programs.
 2. Outline resources offered through pharmaceutical companies available to the low income, uninsured or underinsured population.
 3. Describe procedures commonly used in the process of obtaining medication assistance for those in need.
-

3:00 PM

Acute Brain Dysfunction (Delirium) and Post-ICU Syndrome

Ann Marie Prazak, MS, PharmD, BCPS

Critical Care Pharmacy Specialist, University of Utah Hospital

Tyler Sledge, PharmD

Critical Care Pharmacy Specialist, University of Utah Hospital

0167-0000-13-025-L01-P

Objectives (pharmacists)

1. Define delirium and describe its clinical implications in critically ill adult patients.
 2. List two pharmacologic strategies for prevention of delirium in the critically ill population.
 3. Outline three pharmacologic agents used in the treatment of delirium based upon recent evidence and guidelines.
 4. Define the post-intensive care syndrome (PICS).
 5. Identify three sequelae of patients who develop PICS.
 6. Describe the role of the pharmacist in preventing and managing PICS.
-

3:00 PM

Medical Marijuana: Blowing Away the Smoke

Chris Stock, PharmD, BCPP

Clinical Pharmacy Specialist, Substance Abuse Programs, George E. Wahlen VA Medical Center

0167-0000-13-024-L04-P/T

Objectives (pharmacists)

1. Define “drug” according to the US Code and FDA regulations.
2. Compare the compositions of typical marijuana, Marinol and Sativex.
3. Analyze a patient’s drug regimen for possible drug interactions with marijuana.
4. Formulate information that might be included in a Medication Guide that would help patients who use marijuana do so safely.
5. Adopt a professionally defensible position regarding medical marijuana.

Objectives (technicians)

1. Define “drug” according to the US Code and FDA regulations.
 2. Locate states that allow the use of marijuana for medicinal purposes.
 3. List one medication that cannot be used during therapy with medical marijuana.
-

4:00 PM

Pharmacy Advocacy: Physician Dispensing Laws in Utah

Missy Duke, PharmD, MS, BCPS

Clinical Pharmacy Services Manager, Intermountain Healthcare

0167-0000-13-033-L03-P/T

Objectives (pharmacists and technicians)

1. Describe the current status of physician dispensing laws in Utah.
2. List the bills that have affected physician dispensing.
3. Using a “town hall” format, describe provisions for future legislation on physician dispensing.

Conference Details

Registration: Registration fees are discounted before September 1, 2013. To register, complete the registration form and pay by credit card (online only) or send a check to: USHP, PO Box 58356, Salt Lake City, Utah 84158. Space is Limited! Register Early. Registration fee includes admittance to all programming, exhibits, and group meal functions.

Registrations received after the September 1st deadline or on site are subject to a \$40 additional processing fee.

CE Credit: To obtain up to 7 credits of continuing pharmacy education credit (.70 CEUs), the participant must attend the conference, check in at the registration desk, complete and turn in the attendance and evaluation forms, and pass each assessment test with a 75% or higher score. Attendance forms not turned in on site will not be accepted for credit. All credit will be awarded through participants' CPE Monitor accounts. Credits will be uploaded within 60 days after the program.

Cancellation Policy: To receive partial or full refund, registrants must contact USHP in writing prior to September 1, 2013. Requests made after September 1st may not be considered.

Exhibits: The exhibit area offers an opportunity to learn about the latest from the pharmaceutical industry. Representatives from pharmaceutical manufacturers, wholesalers and others may be on hand to demonstrate new products and services.

Special Assistance: It is USHP's policy to comply with the American's with Disabilities Act. If you have any special needs or services while attending, please contact USHP no later than September 1, 2013 at ushp@ushp.org.

Parking: Parking is complimentary and is located adjacent to the building. Directions to the facility will be available on the USHP website (www.ushp.org) prior to the conference.

Accommodations: If you are in need of overnight accommodations, please USHP at ushp@ushp.org.

No grant funding has been sought for this educational program



The Utah Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.